Natural Killer Cells and Polycythemia Vera (Vaquez's Disease)
This trial is active, not recruiting.
|Sponsor||Assistance Publique Hopitaux De Marseille|
|Start date||July 2009|
|End date||July 2013|
|Trial size||27 participants|
|Trial identifier||NCT01284712, 2009-A00395-52, 2009/16|
Natural Killer cells (NK) are pivotal cells of innate immunity, that sense defective expression of HLA class I molecules and are complementary to specific cytotoxic T lymphocytes. A defect in NK cell cytotoxicity has been described in some hematopoietic malignancies such as acute myeloid leukemia, multiple myeloma, myelodysplastic syndroms. This defect is at least partially linked to a decreased or absent expression of some activating NK cell molecules, more particularly the so-called Natural Cytotoxicity Receptors (NCRs) NKp30, NKp44 and NKp46. Some old publications have demonstrated defective NK cytotoxicity in myeloproliferative syndroms (chronic myeloid leukemia, primary thrombocytosis, polycythemia vera). The investigators more particularly focused their attention on polycythemia vera (Vaquez's disease), a myeloproliferative disease characterized by the recently describet mutation V617F of the JAK2 tyrosine kinase. The investigators will precise the mechanisms leading to this cytotoxicity defect, the investigators also will evaluate the implication of V617F mutation on NK physiology, and will study the interactions between NK cells and hematopoietic progenitors.
To describe immunologic anomalies in polycythemia vera
time frame: 2 years
Male or female participants at least 18 years old.
Inclusion Criteria: - Polycythemia vera - Treatment by therapeutic bleedings - No cytotoxic treatment during the previous six months Exclusion Criteria: - No Polycythemia vera - No treatment by therapeutic bleedings - Cytotoxic treatment during the previous six months
|Principal investigator||Regis Costello|
Call for more information